Bariatric Surgery Reduces Risk Factors for Development of Type 2 Diabetes Mellitus in Morbidly Obese, Nondiabetic Patients

2013 ◽  
Vol 11 (6) ◽  
pp. 441-446 ◽  
Author(s):  
Torunn Kristin Nestvold ◽  
Erik Waage Nielsen ◽  
Knut Tore Lappegård
2014 ◽  
Vol 24 (6) ◽  
pp. 927-935 ◽  
Author(s):  
Rouzbeh Mostaedi ◽  
Denise E. Lackey ◽  
Sean H. Adams ◽  
Stephen A. Dada ◽  
Zahid A. Hoda ◽  
...  

2011 ◽  
Vol 212 (4) ◽  
pp. 505-511 ◽  
Author(s):  
Nestor de la Cruz-Muñoz ◽  
Sarah E. Messiah ◽  
Kristopher L. Arheart ◽  
Gabriela Lopez-Mitnik ◽  
Steven E. Lipshultz ◽  
...  

2014 ◽  
Vol 3 (3) ◽  
pp. 167-75
Author(s):  
Morteza Ghoghaei ◽  
Elias Khajeh ◽  
Foad Taghdiri ◽  
Mohammad Mahdi Zamani ◽  
Soudeh Taghdiri ◽  
...  

 Background: Surgically induced weight loss is a treatment option for the management of obesity and the related common disorders. This study evaluated the beneficial effects of bariatric surgery on metabolic profile and the prevalence of metabolic syndrome (MetS) among Iranian patients.Materials and Methods: A prospective observational study was performed on 26 morbidly obese patients scheduled for bariatric surgery, using laparoscopic Roux-en-Y gastric bypass (LRYGB). The parameters of hypertension, type 2 diabetes mellitus (T2DM), hyperlipidemia, MetS prevalence, and anthropometric measurements of Iranian patients, were recorded, at the preoperative visit and in follow-ups. The follow-up was performed for a median of 12 months, and the change in MetS prevalence and its componnts were assesed.Results: LRYGB induced a mean weight loss of 69.0±21.2%, after 12 months. Preoperative MetS was diagnosed in 21 patients (84%) and decreased to 6 patients (24%) after LRYGB (P=0.001). Likewise, the prevalence of hypertension was significantly decreased from 76% (pre-LRYGB values) to 20% (post-LRYGB values) (P=0.001). The prevalence of T2DM was also decreased from 20% to 8% (P=0.5).Conclusion: According to our results, RYGB produced a rapid and significant weight loss and improvement in hypertension and MetS within one year but there was a controversy about the improvement of T2DM, in Iranian morbidly obese patients.


2019 ◽  
Vol 1 (2) ◽  
pp. 29-34
Author(s):  
Kulvinder Kochar Kaur ◽  

With the increase in epidemic of obesity, the incidence of type 2 diabetes mellitus (T2DM) is increasing globally so much that the need has arisen for treating the two diseases together with the term diabesity getting coined. Here, we have tried to sub-classify T2DM stage-wise and how the treatment should be aimed keeping in view the use of weight-neutral anti-diabetic drugs. Preferably, insulin needs to be avoided due to its weight gaining effects and use of liraglutide should be preferred in the heavily obese diabetics due to its weight lowering effects. If the patient is in stage 4 group where insulin is practically non-existent, one can try using anti-obesity drugs along with insulin or see which works better with the influence of bariatric surgery seen on controlling diabetes in morbidly obese subjects.


Sign in / Sign up

Export Citation Format

Share Document